The decision of the U.S. Supreme Court in Association for Molecular Pathology v. Myriad Genetics, Inc.1 was a landmark case addressing the subject matter provisions in Section 101 of the United States’ Patent Act.2 Represented by public-interest litigators from the American Civil Liberties Union (ACLU) and the Public Patent Foundation, a coalition of scientists, cancer patients, and genetic counselors successfully challenged and invalidated patents covering genetic DNA sequences. The Supreme Court decision drastically revised the understanding of patent-eligible subject matter, with sweeping implications for women’s health, for medical research, and for commercial biotechnology.